(Q38894287)

7 September 2017

1 reference

title

Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy (English)

1 reference

7 September 2017

Eric W-F Lam

15

0 references

author name string

Min Yan

1

1 reference

7 September 2017

Chunli Wang

2

1 reference

7 September 2017

Bin He

3

1 reference

7 September 2017

Mengying Yang

4

1 reference

7 September 2017

Mengying Tong

5

1 reference

7 September 2017

Zijie Long

6

1 reference

7 September 2017

Bing Liu

7

1 reference

7 September 2017

Fei Peng

8

1 reference

7 September 2017

Lingzhi Xu

9

1 reference

7 September 2017

Yan Zhang

10

1 reference

7 September 2017

Dapeng Liang

11

1 reference

7 September 2017

Haixin Lei

12

1 reference

7 September 2017

Sen Subrata

13

1 reference

7 September 2017

Keith W Kelley

14

1 reference

7 September 2017

Bilian Jin

16

1 reference

7 September 2017

Quentin Liu

17

1 reference

7 September 2017

language of work or name

1 reference

13 July 2016

1 reference

Medicinal Research Reviews

7 September 2017

published in

1 reference

7 September 2017

volume

36

1 reference

7 September 2017

issue

6

1 reference

7 September 2017

page(s)

1036-1079

1 reference

Aurora-kinase inhibitors as anticancer agents

7 September 2017

cites work

1 reference

Aurora-A - a guardian of poles

21 January 2018

1 reference

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

21 January 2018

1 reference

Aurora-A Kinase Maintains the Fidelity of Early and Late Mitotic Events in HeLa Cells

21 January 2018

1 reference

Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis

21 January 2018

1 reference

Aurora A activates D-TACC-Msps complexes exclusively at centrosomes to stabilize centrosomal microtubules

21 January 2018

1 reference

Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry

21 January 2018

1 reference

Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition.

21 January 2018

1 reference

Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells

21 January 2018

1 reference

Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates

21 January 2018

1 reference

A microtubule-independent role for centrosomes and aurora a in nuclear envelope breakdown

21 January 2018

1 reference

Human TPX2 is required for targeting Aurora-A kinase to the spindle

21 January 2018

1 reference

Aurora A, mitotic entry, and spindle bipolarity

21 January 2018

1 reference

CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function

21 January 2018

1 reference

Aurora kinases and protein phosphatase 1 mediate chromosome congression through regulation of CENP-E.

21 January 2018

1 reference

Regulation of APC/CCdc20 activity by RASSF1A-APC/CCdc20 circuitry

21 January 2018

1 reference

Aurora A kinase and its substrate TACC3 are required for central spindle assembly

21 January 2018

1 reference

Aurora A is involved in central spindle assembly through phosphorylation of Ser 19 in P150Glued

21 January 2018

1 reference

APC/C Cdh1 targets aurora kinase to control reorganization of the mitotic spindle at anaphase

21 January 2018

1 reference

Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit

21 January 2018

1 reference

Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner

21 January 2018

1 reference

Linking cell cycle to asymmetric division: Aurora-A phosphorylates the Par complex to regulate Numb localization

21 January 2018

1 reference

Aurora-A acts as a tumor suppressor and regulates self-renewal of Drosophila neuroblasts

21 January 2018

1 reference

Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation.

21 January 2018

1 reference

HEF1-dependent Aurora A activation induces disassembly of the primary cilium

21 January 2018

1 reference

Calmodulin activation of Aurora-A kinase (AURKA) is required during ciliary disassembly and in mitosis

21 January 2018

1 reference

β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma

21 January 2018

1 reference

Pitchfork regulates primary cilia disassembly and left-right asymmetry

21 January 2018

1 reference

Trichoplein and Aurora A block aberrant primary cilia assembly in proliferating cells.

21 January 2018

1 reference

Subcellular localization of the spindle proteins Aurora A, Mad2, and BUBR1 assessed by immunohistochemistry

21 January 2018

1 reference

Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation

21 January 2018

1 reference

Aurora A regulates prometaphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity

21 January 2018

1 reference

Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

21 January 2018

1 reference

MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo

21 January 2018

1 reference

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells

21 January 2018

1 reference

Spindle assembly checkpoint inactivation fails to suppress neuroblast tumour formation in aurA mutant Drosophila.

21 January 2018

1 reference

Cyclin B2 and p53 control proper timing of centrosome separation

21 January 2018

1 reference

Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling

21 January 2018

1 reference

Aurora kinase targeting in lung cancer reduces KRAS-induced transformation

21 January 2018

1 reference

Control of the G2/M transition

21 January 2018

1 reference

BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition

21 January 2018

1 reference

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells

21 January 2018

1 reference

AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma

21 January 2018

1 reference

Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks

21 January 2018

1 reference

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol

21 January 2018

1 reference

Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73

21 January 2018

1 reference

Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells

21 January 2018

1 reference

Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha

21 January 2018

1 reference

Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway

21 January 2018

1 reference

Aurora kinase A promotes inflammation and tumorigenesis in mice and human gastric neoplasia

21 January 2018

1 reference

Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL.

21 January 2018

1 reference

Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells

21 January 2018

1 reference

Aurora-A down-regulates IkappaBalpha via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival

21 January 2018

1 reference

Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells

21 January 2018

1 reference

Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells

21 January 2018

1 reference

Hesperidin induces apoptosis and triggers autophagic markers through inhibition of Aurora-A mediated phosphoinositide-3-kinase/Akt/mammalian target of rapamycin and glycogen synthase kinase-3 beta signalling cascades in experimental colon carcinogen

21 January 2018

1 reference

Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia

21 January 2018

1 reference

Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells

21 January 2018

1 reference

BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by βTrCP1.

21 January 2018

1 reference

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

21 January 2018

1 reference

Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells

21 January 2018

1 reference

Aurora kinase a suppresses metabolic stress-induced autophagic cell death by activating mTOR signaling in breast cancer cells

21 January 2018

1 reference

The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells

21 January 2018

1 reference

Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells

21 January 2018

1 reference

Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells

21 January 2018

1 reference

The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway

21 January 2018

1 reference

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion

21 January 2018

1 reference

Rac1 and Aurora A regulate MCAK to polarize microtubule growth in migrating endothelial cells

21 January 2018

1 reference

A non-mitotic role for Aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src.

21 January 2018

1 reference

The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma

21 January 2018

1 reference

Overexpression of Aurora-A enhances invasion and matrix metalloproteinase-2 expression in esophageal squamous cell carcinoma cells

21 January 2018

1 reference

Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer

21 January 2018

1 reference

In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells

21 January 2018

1 reference

Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.

21 January 2018

1 reference

A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance.

21 January 2018

1 reference

Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics.

21 January 2018

1 reference

Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma

21 January 2018

1 reference

Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer

21 January 2018

1 reference

Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells

21 January 2018

1 reference

Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype

21 January 2018

1 reference

ConsensusPathDB--a database for integrating human functional interaction networks

21 January 2018

1 reference

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53.

21 January 2018

1 reference

Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215.

21 January 2018

1 reference

p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation

21 January 2018

1 reference

Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function

21 January 2018

1 reference

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

21 January 2018

1 reference

Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma

21 January 2018

1 reference

Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma

21 January 2018

1 reference

The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.

21 January 2018

1 reference

Drugging MYCN through an allosteric transition in Aurora kinase A

21 January 2018

1 reference

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

21 January 2018

1 reference

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis.

21 January 2018

1 reference

Suppression of Aurora-A oncogenic potential by c-Myc downregulation

21 January 2018

1 reference

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

21 January 2018

1 reference

Regulation of the Aurora-A gene following topoisomerase I inhibition: implication of the Myc transcription factor

21 January 2018

1 reference

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

21 January 2018

1 reference

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

21 January 2018

1 reference

Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers.

21 January 2018

1 reference

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer

21 January 2018

1 reference

Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation.

21 January 2018

1 reference

Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer

21 January 2018

1 reference

Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract.

21 January 2018

1 reference

Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma

21 January 2018

1 reference

Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human

21 January 2018

1 reference

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation

21 January 2018

1 reference

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

21 January 2018

1 reference

Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays

21 January 2018

1 reference

Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.

21 January 2018

1 reference

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

21 January 2018

1 reference

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

21 January 2018

1 reference

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment

21 January 2018

1 reference

The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

21 January 2018

1 reference

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

21 January 2018

1 reference

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

21 January 2018

1 reference

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

21 January 2018

1 reference

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-

21 January 2018

1 reference

ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action

21 January 2018

1 reference

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

21 January 2018

1 reference

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

21 January 2018

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias

21 January 2018

1 reference

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

21 January 2018

1 reference

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).

21 January 2018

1 reference

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

21 January 2018

1 reference

AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models

21 January 2018

1 reference

Discovery of a potent and selective aurora kinase inhibitor

21 January 2018

1 reference

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

21 January 2018

1 reference

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

21 January 2018

1 reference

PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy

21 January 2018

1 reference

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

21 January 2018

1 reference

Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.

21 January 2018

1 reference

Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors

21 January 2018

1 reference

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model

21 January 2018

1 reference

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

21 January 2018

1 reference

The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines

21 January 2018

1 reference

Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

21 January 2018

1 reference

Danusertib, an aurora kinase inhibitor

21 January 2018

1 reference

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

21 January 2018

1 reference

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas

21 January 2018

1 reference

Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells

21 January 2018

1 reference

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide

21 January 2018

1 reference

Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A.

21 January 2018

1 reference

Curcumin-induced Aurora-A suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs

21 January 2018

1 reference

Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function

21 January 2018

1 reference

Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function

21 January 2018

1 reference

Ashwagandha derived withanone targets TPX2-Aurora A complex: computational and experimental evidence to its anticancer activity

21 January 2018

1 reference

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237

21 January 2018

1 reference

p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases

21 January 2018

1 reference

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

21 January 2018

1 reference

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer

21 January 2018

1 reference

Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy.

21 January 2018

1 reference

A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines

21 January 2018

1 reference

The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program

21 January 2018

1 reference

Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma

21 January 2018

1 reference

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

21 January 2018

1 reference

The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas

21 January 2018

1 reference

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

21 January 2018

1 reference

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase

21 January 2018

1 reference

The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells

21 January 2018

1 reference

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

21 January 2018

1 reference

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels

21 January 2018

1 reference

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

21 January 2018

1 reference

Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma

21 January 2018

1 reference

Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism

21 January 2018

1 reference

Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.

21 January 2018

1 reference

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

21 January 2018

1 reference

NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors

21 January 2018

1 reference

Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death

21 January 2018

1 reference

Aurora kinase inhibitors: progress towards the clinic

21 January 2018

1 reference

Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).

21 January 2018

1 reference

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas

21 January 2018

1 reference

Nuclear localization of EGF receptor and its potential new role as a transcription factor

21 January 2018

1 reference

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis

21 January 2018

1 reference

LKB1 kinase-dependent and -independent defects disrupt polarity and adhesion signaling to drive collagen remodeling during invasion

21 January 2018

1 reference

Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation

21 January 2018

1 reference

A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines

21 January 2018

1 reference

Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

21 January 2018

1 reference

A comprehensive analysis of Aurora A; transcript levels are the most reliable in association with proliferation and prognosis in breast cancer

21 January 2018

1 reference

Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells

21 January 2018

1 reference

Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer

21 January 2018

1 reference

Assessment of Aurora A kinase expression in breast cancer: a tool for early diagnosis?

21 January 2018

1 reference

Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer

21 January 2018

1 reference

Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas

21 January 2018

1 reference

Aurora-A over-expression in high-grade PIN lesions and prostate cancer

21 January 2018

1 reference

Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification

21 January 2018

1 reference

Expression of Aurora kinase A and B in normal and malignant cervical tissue: high Aurora A kinase expression in squamous cervical cancer.

21 January 2018

1 reference

Correlation between Aurora-A expression and the prognosis of cervical carcinoma patients

21 January 2018

1 reference

Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians

21 January 2018

1 reference

Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis

21 January 2018

1 reference

Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma.

21 January 2018

1 reference

Models of breast cancer: quo vadis, animal modeling?

21 January 2018

1 reference

Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation.

21 January 2018

1 reference

Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma

21 January 2018

1 reference

The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

21 January 2018

1 reference

Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma

21 January 2018

1 reference

Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer

21 January 2018

1 reference

Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma.

21 January 2018

1 reference

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability

21 January 2018

1 reference

Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer

21 January 2018

1 reference

Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme

21 January 2018

1 reference

In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

21 January 2018

1 reference

The cellular geography of aurora kinases

21 January 2018

1 reference

Chromosomal passengers: conducting cell division

21 January 2018

1 reference

The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis

21 January 2018

1 reference

Cell division: control of the chromosomal passenger complex in time and space

21 January 2018

1 reference

The chromosomal passenger complex (CPC) as a key orchestrator of orderly mitotic exit and cytokinesis

21 January 2018

1 reference

The nephronophthisis gene product NPHP2/Inversin interacts with Aurora A and interferes with HDAC6-mediated cilia disassembly

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.21399

1 reference

7 September 2017

1 reference